Mumbai, Sep 28: Health Care At Home India Pvt Ltd and QMS Medical Allied Services Limited, an integrated healthcare solutions company listed on the NSE Main Board, today announced the signing of definitive documents for a strategic merger of their pharma services businesses to create a scaled provider of patient support program solutions for pharmaceutical companies across India. Under the terms, the PSP business verticals of both HCAH and QMS would merge into Saarathi Healthcare, a 100% subsidiary of QMS.
Together, the combined platform will operate 160+ Patient Support Programs impacting over 1.2 million+ patients, supported by 2,000+ professionals across 35+ cities, with complementary capabilities spanning patient screening, enrolment, therapy initiation, adherence, patient assistance and disease management. The combined entity will be India’s largest patient support platform, serving top Indian and MNC pharma companies. The partnership is intended to create a larger and more comprehensive platform while maintaining continuity for existing clients, programs and teams through the transition.
Mahesh Makhija, Founder, Chairman & Managing Director, QMS Medical Allied Services Limited, said:
“The combination brings together two complementary platforms with strong capabilities across patient support and engagement. By bringing these capabilities together, we aim to create greater scale, reach and execution capability for pharmaceutical companies while helping more patients access the support they need throughout their treatment journey. This initiative would also fortify the value creation for the shareholders at QMS.”
Aditya Burman, Non-Executive Director, HCAH, and Director, Dabur India Ltd, said:
“Patient support is increasingly becoming an integral part of the healthcare journey, particularly as chronic conditions require sustained engagement beyond the point of treatment initiation. The combination of HCAH’s and QMS’s capabilities creates a scaled platform with the reach, technology and execution capabilities to support patients and pharmaceutical partners across the continuum of care”
The partnership brings together experience and capabilities spanning health and awareness camps, disease screening, enrolment, disease management, therapy initiation, adherence, patient assistance and ongoing patient engagement. The combined platform will enable pharmaceutical companies to support patients across a broader range of touchpoints throughout the patient journey from identification to therapy adherence.
The global patient support services market is estimated at c.US$70 billion, with the India market growing at a CAGR of 15-20% to reach c.US$1 billion by 2030, driven by tighter promotional regulations, industry formalisation, rising chronic disease prevalence, increasing digital adoption and greater focus on continuous patient monitoring and recovery.
